Floatz logo

Loperamide

Hormone Receptor Positive Tumor

Eli Lilly and CompanySmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

92 Active assets in the Hormone Receptor Positive Tumor cohort.

Asset / SponsorPhaseRating
FULVESTRANT
Relay Therapeutics, Inc.
Phase 3BB
Abemaciclib
Relay Therapeutics, Inc.
Phase 2BB
Ribociclib
Relay Therapeutics, Inc.
Phase 3BB
Palbociclib
Relay Therapeutics, Inc.
Phase 2BB
Letrozole
Relay Therapeutics, Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

Loperamide is also rated in:

diarrheal diseaseDormant
BB
Indicative ·
66 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
B
Indicative ·
62 / 100
View asset →
breast cancerDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →